The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL159464     3-(3-methylaminopropylamino) propylsulfanyl...

Synonyms: AG-H-29172, NSC-335662, CTK3E8497, NSC335662, AR-1L3353, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of AIDS-010086

  • Suppression of HIV expression by WR-151327 was observed in the absence of a cytotoxic or cytostatic effect [1].
  • WR-151327 increases resistance to Klebsiella pneumoniae infection in mixed-field- and gamma-photon-irradiated mice [2].
  • In addition, WR-151327 suppressed HIV-LTR-CAT activity in transfected human rhabdomyosarcoma cells (RD) [1].
  • PURPOSE: To determine the efficacy of WR-151327 (WR) [S-3-(3-methylaminopropylamino) propylphosphorothioic acid; (CH3-HN-(CH2)3-NH-(CH2)3-S-PO3H2)] in increasing resistance to bacterial infection after a sublethal dose of gamma-photons or mixed-field neutrons plus gamma-photons [2].
  • The calculated radioprotective dose reduction factors (DRF) at 450 mg per kg and 900 mg per kg of body weight (BW) WR-151327 were 1.2 and 1.3, respectfully [3].

High impact information on AIDS-010086

  • Incubation of WR-151327 with human recombinant TNF-alpha for 6 hr at 37 degrees C did not alter the capacity of TNF-alpha to induce the expression of HIV [1].
  • We present data which show the effects of the organic thiophosphate WR-151327 on the expression of latent HIV in U1 cells [1].
  • Histopathological effects of WR-151327 were restricted to the testes, salivary gland, and pancreas [4].
  • Small but significant sex differences in radioprotection were found: the DMFs for female mice pretreated with either compound were lower than those for similarly treated male mice; the incidence of mortality 31-100 days postexposure in male mice pretreated with WR-151327 was greater than for female mice [5].
  • Two thiophosphoroate radiation protectors (WR-2721 and WR-151327) were assessed for their ability to modify the effects of neutron or gamma irradiation on the gastrointestinal tract [6].

Anatomical context of AIDS-010086

  • Moreover, there was a dramatic reduction in the germinal cells in mice seminiferous tubules treated with a combination of 450 mg per kg WR-151327 plus 10 Gy radiation after eight days [3].

Associations of AIDS-010086 with other chemical compounds

  • In protection studies, groups of mice were treated with the phosphorothioate WR-151327 (200 mg/kg, 25% of the LD(10)) or the immunomodulator, synthetic trehalose dicorynomycolate (S-TDCM; 8 mg/kg), before lethal irradiation with reactor-generated fission neutrons and gamma-rays (n/gamma=1) or 60Co gamma-rays [7].

Analytical, diagnostic and therapeutic context of AIDS-010086


  1. Organic thiophosphate WR-151327 suppresses expression of HIV in chronically infected cells. Kalebic, T., Schein, P.S. AIDS Res. Hum. Retroviruses (1994) [Pubmed]
  2. WR-151327 increases resistance to Klebsiella pneumoniae infection in mixed-field- and gamma-photon-irradiated mice. Ledney, G.D., Elliott, T.B., Harding, R.A., Jackson, W.E., Inal, C.E., Landauer, M.R. Int. J. Radiat. Biol. (2000) [Pubmed]
  3. Pathological evaluation of WR-151327 administered orally in irradiated and non-irradiated male mice. Steel-Goodwin, L., Kendrick, J.M., Egan, J.E., Eckstein, J.M. Ann. Clin. Lab. Sci. (1992) [Pubmed]
  4. Pathological effects of the radiation protector WR-151327 in mice. van Beek, M.E., Doak, R.L., Sigdestad, C.P., Grdina, D.J. Radiat. Res. (1990) [Pubmed]
  5. Protection of mice against fission neutron irradiation by WR-2721 or WR-151327. Steel, L.K., Jacobs, A.J., Giambarresi, L.I., Jackson, W.E. Radiat. Res. (1987) [Pubmed]
  6. A comparison of radioprotection from three neutron sources and 60Co by WR-2721 and WR-151327. Sigdestad, C.P., Grdina, D.J., Connor, A.M., Hanson, W.R. Radiat. Res. (1986) [Pubmed]
  7. Survival of irradiated mice treated with WR-151327, synthetic trehalose dicorynomycolate, or ofloxacin. Ledney, G.D., Elliott, T.B., Landauer, M.R., Vigneulle, R.M., Henderson, P.L., Harding, R.A., Tom, S.P. Advances in space research : the official journal of the Committee on Space Research (COSPAR). (1994) [Pubmed]
  8. Preclinical evaluation of WR-151327: an orally active chemotherapy protector. Green, D., Bensely, D., Schein, P. Cancer Res. (1994) [Pubmed]
  9. Chromatographic and mass spectral analysis of the radioprotector and chemoprotector S-3-(3-methylaminopropylamino)propanethiol (WR-151326) and its symmetrical disulfide (WR-25595501). Vaishnav, Y.N., Pendergrass, J.A., Clark, E.P., Swenberg, C.E. Journal of pharmaceutical and biomedical analysis. (1996) [Pubmed]
WikiGenes - Universities